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Abstract
AIM: To investigate expression of microRNA (miRNA) 
and potential targets in chemotherapy resistant esoph-
ageal cancer cell lines.
METHODS: An in-vitro  model of acquired chemother-
apy resistance in esophageal adeno- (EAC) and squa-
mous cell carcinoma (ESCC) cells was used, and mi-
croRNA expression profiles for cisplatin or 5-fluorouracil 
(5-FU) resistant variants vs  chemotherapy sensitive 
controls were compared using microarray and quanti-
tative real-time polymerase chain reaction (PCR). The 
expression of chemotherapy-relevant genes potentially 
targeted by the dysregulated microRNAs in the chemo-
therapy resistant variants was also evaluated. 
RESULTS: Chemotherapy resistant sublines were found 
to have specific miRNA signatures, and these miRNA 
signatures were different for the cisplatin vs  5-FU re-
sistant cells from the same tumor cell line, and also for 
EAC vs  ESCC cells with resistance to the same specific 
chemotherapy agent. Amongst others, miR-27b-3p, 
miR-193b-3p, miR-192-5p, miR-378 a-3p, miR-125a-
5p and miR-18a-3p were dysregulated, consistent with 
negative posttranscriptional control of KRAS, TYMS, 
ABCC3, CBL-B and ERBB2 expression via  these miRNAs.
CONCLUSION: The current study supports the hy-
pothesis that microRNA expression has an impact on 
chemotherapy resistance in esophageal cancer. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: The current study demonstrates that chemo-
therapy resistant esophageal adeno- and squamous cell 
carcinoma cells present distinct microRNA (miRNA) sig-
natures, with a number of well known resistance rele-
vant miRNAs differentially expressed in the derived cis-
platin or 5-fluorouracil  resistant cell lines. Furthermore, 
a number of putative target genes that are known to 
have an impact on chemotherapy resistance are dys-
regulated in the chemotherapy resistant cell lines in a 
direction consistent with negative posttranscriptional 
control of target gene expression via  the respective 
miRNA, thereby implicating a potential mediatory effect 
in terms of chemotherapy resistance development.
Hummel R, Sie C, Watson DI, Wang T, Ansar A, Michael MZ, 
Van der Hoek M, Haier J, Hussey DJ. MicroRNA signatures in 
chemotherapy resistant esophageal cancer cell lines. World J 
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INTRODUCTION
Esophageal cancer is the eighth most common cancer 
worldwide, and the sixth most common cause of  cancer 
related death [GLOBOCAN 2008 (IARC), Section of  
Cancer Information (30/1/2012)]. Despite improve-
ments in the management of  esophageal cancer, how-
ever, the outcome for individuals developing this disease 
remains poor. Chemotherapy and/or radiotherapy based 
treatment approaches are used in many patients, and re-
cently several meta-analyses have demonstrated a survival 
advantage for patients undergoing either neoadjuvant 
chemotherapy or combined chemo-radiotherapy treat-
ment before surgery for esophageal cancer, compared to 
surgery alone[1,2]. In addition, in patients not suitable for 
surgical resection, combined chemo-radiotherapy is fol-
lowed by complete macroscopic tumor regression, when 
assessed by endoscopy, in up to 50% of  patients, with a 
partial response achieved in approximately half  of  the re-
maining patients[3]. However, individuals respond to these 
treatments in a variable fashion, and those who respond 
poorly to chemotherapy probably undergo futile treat-
ment. Identification of  individuals who are unlikely to 
benefit before treatment starts is desirable as it would al-
low treatment to be tailored to the individuals most likely 
to benefit. It is possible that novel molecular biomarkers, 
which predict response to chemotherapy, might be iden-
tifiable and might be then used to tailor treatment. It is 
also possible that molecular biomarkers of  chemotherapy 
response might provide novel therapeutic targets to over-
come potential chemotherapy resistance. 
In this context, microRNA (miRNA) biomarkers 
are promising candidates. It has been demonstrated 
that miRNA expression profiles differ between various 
esophageal derived tissues, correlate with prognosis and 
clinico-pathological features in esophageal cancer, and 
impact directly on tumor growth, tumor cell prolifera-
tion, and tumor invasion[4,5]. In addition, for some other 
cancer types there is evidence that miRNA expression 
has an impact on the response to chemotherapy[6], but so 
far there is very little data available from studies evaluat-
ing esophageal cancer in this context. 
To investigate this further, we sought associations be-
tween miRNA expression and response to chemotherapy 
in esophageal cancer. Specifically, we assessed whether 
chemotherapy resistant esophageal cancer cells exhibit 
a specific miRNA expression pattern, and whether the 
expression of  potential chemotherapy resistance-relevant 
targets of  the dysregulated miRNAs is altered in chemo-
therapy resistant cancer cells.
MATERIALS AND METHODS
Cell lines and cell culture
The chemotherapy sensitive human adenocarcinoma 
(EAC) cell line OE19 and the squamous cell carcinoma 
(ESCC) cell line KYSE410, and cisplatin and 5-Fluoro-
uracil (5-FU) resistant variants of  both cell lines which 
were developed in our laboratory, were used for the cur-
rent study. Resistant sublines of  both sensitive cell lines 
were generated using a pulsatile treatment approach 
which included repetitive treatment of  cells with con-
stant concentrations of  cisplatin or 5-FU. Briefly, KYSE 
410 cells were subjected to a 4-d exposure of  2 µmol/L 
cisplatin or 5 µmol/L 5-FU, and OE 19 cells were ex-
posed to 5 µmol/L cisplatin or 10 µmol/L 5-FU for 
3 d. The medium was not changed during this period, 
thereby providing a constant exposure to the chemothe-
rapy agent. After removal of  the chemotherapy agent, 
cells were allowed to recover, split when approximately 
70%-80% confluent, and then exposed to the next cycle 
of  chemotherapy. All derived cell lines were shown to 
have significant resistance to the corresponding chemo-
therapy agent[7]. 
Cells were cultured in a humidified atmosphere con-
taining 5% CO2 at 37 ℃, using DMEM high glucose/
phenol red free DMEM/F12 1:1 medium (OE-19) or 
1 × RPMI 1640/phenol red free RPMI 1640 medium 
(KYSE410) supplemented with 10% fetal bovine se-
rum, 1% Penicillin-Streptomycin (GIBCO® Invitrogen, 
Life Technologies Australia Pty Ltd., Victoria, Australia) 
and 2‰ Normocin™ (InvivoGen, Life Research Pty 
Ltd, Victoria, Australia). Resistant variants were further 
repeatedly exposed to the respective chemotherapeutic 
agent as outlined above in order to maintain the selection 
pressure[7].
Cell harvest, RNA extraction and preparation
Cells from the chemotherapy resistant variants and their 
original cell line were seeded into 6 replicate flasks each. 
Prior to harvest, resistant cell lines were allowed to grow 
for at least 24-48 h in chemotherapy-free medium in 
order to avoid an acute toxicity response to the respec-
tive chemotherapeutic agent. Then, cells were harvested 
at a confluency of  about 80% in TRIzol® (Invitrogen) 
and total RNA was extracted from the cells according 
to the manufacturer’s protocol. RNA concentration was 
measured using UV spectrophotometry (NanoDrop® 
ND-8000 Spectrophotometer, Thermo Fisher Scientific), 
and quality determined by visualization of  distinct 28S 
and 18S rRNA species via electrophoresis through a 1% 
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agarose gel. 
miRNA microarray
500 ng of  total RNA was used for microarray studies. 
Total RNA was labeled using the FlashTag HSR Biotin 
RNA Labelling Kits (Genisphere LLC. Hatfield) and 
hybridized to microRNA Arrays (Affymetrix GeneChip 
miRNA Array which contained 848 miRNAs represent-
ing Sanger miRBase v11, Affymetrix Inc.) as per the 
Genisphere manual.  Briefly, RNA was poly-A tailed, 
and then a proprietary biotin-labelled dendramer mol-
ecule was joined to the 3’ end using DNA ligase. Labeled 
samples were hybridized to the arrays at 48 ℃ for 16 h 
and then washed and stained with a Steptavidin-PE solu-
tion prior to imaging. The resultant CEL files containing 
the raw intensity data were background corrected and 
statistically analyzed using Partek Genomics Suite (Partek 
Inc. St Louis, United States) using the subset of  human 
targeting probes on the array. Raw data was processed 
using Robust Multichip Average (RMA) background 
correction, quantile normalization and probe summariza-
tion. Differential miRNA expression was determined by 
ANOVA (analysis of  variance) with the p-value adjusted 
using the step-up multiple test correction. The step-up 
method used was the Benjamini_Hochberg method for 
multiple test correction, which is widely used for micro-
array data analysis[8]. Adjusted P < 0.05 were considered 
to be significant. Microarray data were deposited in the 
Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo; 
GEO accession number GSE50224). Subsequently, the 
most significantly dysregulated miRNAs from the micro-
array experiments for each resistant cell line were selected 
and expression of  these candidates was assessed via quan-
titative real-time polymerase chain reaction (PCR). 
DNase-pretreatment, reverse transcription and quantita-
tive real-time PCR for miRNA validation
For quantitative real-time PCR validation, all samples 
underwent DNase-pretreatment using Ambion® TURBO 
DNA-free™ (Applied Biosystems) in order to remove 
contaminating DNA. 500 ng of  RNA dissolved in 8 µL 
nuclease free water was incubated with 1 µL 10 × Turbo 
DNase Buffer and 1 µL rDNase I for 30 min at 37 ℃ in 
a thermocycler (Eppendorf  Mastercycler). Samples were 
then incubated with 1 µL DNase Inactivation Reagent 
for 5 min at room temperature, and centrifuged at 10000 
g for 5 min at 4 ℃. DNase treated RNA was finally incu-
bated for 10 min at 75ºC, and stored on ice for further 
processing.
The miScript Reverse Transcription Kit (Qiagen) was 
used, as it allows quantification of  mature miRNA and 
mRNA from the same cDNA sample. 500 ng of  DNase 
treated RNA was combined with 4 µL miScript 5x RT 
Buffer, 1 µL Reverse Transcriptase and 5 µL nuclease 
free water before incubation (protocol: 60 min at 37 ℃, 
5 min at 95 ℃, then hold at 4 ℃). For miRNA validation 
via quantitative real-time PCR (PCR), the miScript PCR 
system was used, and 5 µL of  cDNA was mixed with 10 
µL 2 × QuantiTect SYBR, 2 µL 10 × miScript Universal 
Primer, 2 µL gene specific 10 × miScript Primer Assay, 
and 1 µL nuclease free water. Quantitative analysis was 
performed using Q-Gene software. MiRNA expression 
data was normalized to the expression levels of  RNU44, 
which displayed comparable expression across the differ-
ent groups (data not shown).
Gene expression of potential targets on mRNA levels
To evaluate the functional relevance of  the miRNAs that 
were identified to be dysregulated in the development of  
chemotherapy resistance, we next performed gene ex-
pression analyses of  the mRNA levels for putative targets 
of  these miRNAs. In this context, potential gene targets 
of  the dysregulated miRNAs were identified from the 
literature and bioinformatics tools (DIANA-mirPath[9]), 
and we focused on genes that were known to be relevant 
to cellular resistance to chemotherapy (cisplatin resistant 
EAC: ZEB1/ZEB 2[10], Bcl-2[11], DUSP16[12], KRAS[13], 
MAP4K4[14]; 5-FU resistant EAC: KRAS[13], CDKN1b[15], 
TYMS[16], ABCC3[17], CBL-B[18]; 5-FU resistant ESCC: 
ERBB2/ERBB3[19], MUC1[20], MAP4K4[14], KRAS[13]). To 
determine the mRNA levels, the same cDNA that was 
used for the determination of  miRNA expression lev-
els was used (see section “DNase-pretreatment, reverse 
transcription and quantitative real-time PCR (qPCR) for 
miRNA validation”). TaqMan® Assays (Applied Biosys-
tems) were used as follows: 3 µL of  cDNA was mixed 
with 10 µL TaqMan® Gene Expression Master Mix (× 2), 
1 µL of  the respective TaqMan® Primer (× 20) and 6 µL 
nuclease free water. All samples were assayed in triplicate 
reactions using a Rotorgene 6000 thermocycler (Corbett 
Life Science). Quantitative analysis was performed using 
Q-Gene software. mRNA expression data was normal-
ized to 18S rRNA, which displayed comparable expres-
sion across the different groups (data not shown). 
Statistical analysis
Expression data for miRNAs/mRNAs were expressed 
as means of  normalized expression with standard devia-
tion. These data were assessed for statistical significance 
using Student’s t-test for equal and unequal variances, 
as appropriate, based on Levene’s test for homogeneity 
of  variances. P ≤ 0.05 was considered to be statistically 
significant. Analyses were performed using SPSS 17.0 for 
Windows (SPSS, Chicago, IL).
RESULTS
miRNA signature of chemotherapy resistant esophageal 
cancer: Microarray results
The results of  the miRNA microarray experiments are 
summarized in Figure 1 and Table 1. A large number of  
miRNAs that were dysregulated in the different chemo-
therapy resistant cell lines were identified, compared to 
the chemotherapy sensitive controls.  In cisplatin resistant 
EAC cells, 18 miRNAs were significantly dysregulated 
compared to controls (13 downregulated, 5 upregulated). 
14906 October 28, 2014|Volume 20|Issue 40|WJG|www.wjgnet.com
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Cis       Cis         Cis       Cis        Cis       Cis        Con      Con        Con      Con       Con      Con
KYSE Cis
hsa-miR-130a_st
hsa-miR-18a-star_st
hsa-miR-339-5p_st
hsa-miR-744_st
hsa-miR-99b_st
hsa-miR-193b_st
hsa-miR-25_star_st
hsa-miR-92a_st
hsa-miR-320c_st
hsa-miR-320b_st
hsa-miR-320a_st
FU       FU         FU        FU        FU        FU        Con      Con       Con      Con       Con      Con
KYSE FU
hsa-miR-1292_st
hsa-miR-550_st
hsa-miR-550-star_st
hsa-miR-410_st
hsa-miR-196b_st
hsa-miR-1226_st
hsa-miR-331-3p_st
hsa-miR-935_st
hsa-miR-18a-star_st
hsa-miR-125a-5p_st
hsa-miR-99b_st
hsa-miR-663_st
Cis       Cis       Cis       Cis       Cis       Cis      Con      Con      Con     Con      Con      Con
OE19 Cis
hsa-miR-92b-star_st
hsa-miR-296-3p_st
hsa-miR-663_st
hsa-miR-638_st
hsa-miR-191_st
hsa-miR-203_st
hsa-miR-200a_st
hsa-miR-181a_st
hsa-miR-532-5p_st
hsa-miR-200b_st
hsa-miR-455-3p_st
hsa-let-7a_st
hsa-miR-200b-star_st
hsa-miR-125a-5p_st
hsa-miR-181b_st
hsa-miR-23a_st
hsa-let-7e_st
hsa-miR-31_st
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In cisplatin resistant ESCC cells, 8 miRNAs were signifi-
cantly dysregulated (all 8 downregulated). In 5-FU resis-
tant EAC cells, 18 miRNAs were significantly dysregulat-
ed (10 downregulated, 8 upregulated). In 5-FU resistant 
ESCC cells, 5 miRNAs were significantly dysregulated (3 
downregulated, 2 upregulated). 
miRNA signature in chemotherapy resistant esophageal 
cancer cells: Quantitative real-time PCR  validation
Quantitative real-time PCR validation of  the microarray 
experiments validated significant up- and downregulation 
for 11 miRNAs in cisplatin resistant EAC cells, 9 miR-
NAs in 5-FU resistant EAC cells, 1 miRNA in cisplatin 
resistant ESCC cells and 6 miRNAs in 5-FU resistant 
ESCC cells (Table 2). More miRNAs were downregulated 
in resistant cells compared to sensitive controls (19 down-
regulated vs 8 upregulated miRNAs). Two miRNAs were 
found to have altered expression in both cisplatin and 
5-FU resistant cells: miR-31 and miR-125a-5p. Interest-
ingly, miR-31-5p was downregulated in cisplatin resistant 
EAC but upregulated in 5-FU resistant EAC, whereas 
miR-125a-5p expression was suppressed in both, cisplatin 
resistant EAC and 5-FU resistant ESCC variants.
mRNA expression levels of potential target genes
The expression of  potential target genes for the dysregu-
lated miRNAs was examined for 19 putative target can-
didates. Significant up- or downregulation of  9 of  these 
19 targets were found in the respective cell lines (5-FU 
resistant EAC: KRAS, TYMS, ABCC3 and CBL-B; cispl-
atin resistant EAC: BCL-2 and MAP4K4; 5-FU resistant 
ESCC: ERBB2, MUC1 and KRAS). Comparison be-
tween target gene expression and miRNA expression re-
vealed that 6 targets (KRAS, TYMS, ABCC3 and CBL-B 
in 5-FU resistant EAC; ERBB2 and KRAS in 5-FU 
resistant ESCC) were regulated in a direction consistent 
with negative post-transcriptional control of  target gene 
expression via the respective miRNA (Table 3).
DISCUSSION
miRNAs represent a new class of  epigenetic regulators 
of  global gene expression, and their expression appears 
to influence chemotherapy sensitivity and resistance[6]. 
In the current study, miRNA microarrays were used to 
evaluate global miRNA expression profiling within an 
in-vitro model of  acquired chemotherapy resistance in 
esophageal EAC and ESCC cells, and then quantitative 
real-time PCR was used to validate the findings. This 
demonstrated specific miRNA signatures for each che-
motherapy resistant subline, and that the miRNA sig-
natures are different for cisplatin vs 5-FU resistant cells 
from the same tumor cell line, and also for EAC vs ESCC 
cells with resistance to the same specific chemotherapy 
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FU       FU         FU        FU        FU        FU        Con      Con       Con      Con       Con      Con
OE19 FU
hsa-miR-21-star_st
hsa-miR-25-star_st
hsa-miR-663_st
hsa-miR-1275_st
hsa-miR-1268_st
hsa-miR-193b_st
hsa-miR-222_st
hsa-miR-31_st
hsa-miR-455-5p_st
hsa-miR-27b_st
hsa-miR-17-star_st
hsa-miR-203_st
hsa-miR-210_st
hsa-miR-378_st
hsa-miR-17_st
hsa-miR-18a_st
hsa-miR-192_st
hsa-miR-194_st
Figure 1  Microarray results. The figure summarises the miRNA microarray results in the different resistant cell lines, showing the comparison of miRNA expression 
between 6 replicate experiments and controls for each resistant cell line. A: Cisplatin resistant esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells 
vs chemotherapy sensitive controls; B: 5-FU resistant ESCC cells vs chemotherapy sensitive controls; C: Cisplatin resistant EAC cells vs chemotherapy sensitive con-
trols; D: 5-FU resistant EAC cells vs chemotherapy sensitive controls. Cis: Cisplatin resistant cells; FU: 5-FU resistant cells; Con: Sensitive control cells.
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Table 1  Dysregulated microRNAs in resistant cells: Microarray results
EAC ESCC
miRNA Stepup P -value Fold-change miRNA Stepup P -value Fold-change
Dysregulated microRNAs in 
cisplatin-resistant variants
miR-181a-5p 0.00141 -1.78 miR-320a 0.002 -1.75
miR-125a-5p 0.00169 -2.23 miR-320b 0.002 -1.76
let-7e-5p 0.00170 -2.21 miR-320c 0.002 -1.66
miR-181b-5p 0.00170 -1.68 miR-744-5p 0.023 -1.90
miR-200b-3p 0.00170 -5.38 miR-99b-5p 0.023 -1.70
miR-31-5p 0.00188 -1.57 miR-92a-3p 0.030 -1.53
miR-200b-5p 0.00278 -5.11 miR-25-5p 0.041 -2.52
miR-455-3p 0.00510 -2.78 miR-339-5p 0.047 -1.60
miR-191-5p 0.00934  1.30 miR-18a-3p 0.056 -2.42
miR-638 0.00934  1.74 miR-193b-3p 0.062 -1.73
miR-92b-5p 0.01344  1.79 miR-130a-3p 0.077 2.28
miR-23a-3p 0.01799 -2.31
miR-200a-3p 0.03240 -5.05
miR-296-3p 0.04236  1.66
let-7a-5p 0.04236 -1.87
miR-203a 0.04236 -2.84
miR-663a 0.04480  2.40
miR-532-5p 0.04913 -2.44
Dysregulated microRNAs in 5-FU-
resistant variants
miR-31-5p 0.00031  1.84 miR-550 a-5p 0.001 3.23
miR-192-5p 0.00151 -2.57 miR-935 0.008 -3.69
miR-194-5p 0.00151 -2.55 miR-550 a-3p 0.037 2.65
miR-378 a-3p 0.00277 -3.17 miR-99b-5p 0.045 -1.70
miR-222-3p 0.00277  2.06 miR-18a-3p 0.047 -2.71
miR-210-3p 0.00289 -2.90 miR-1226-3p 0.072 -2.45
miR-18a-3p 0.00456 -1.84 miR-1292-5p 0.072 1.77
miR-21-3p 0.00556  2.53 miR-125a-5p 0.127 -1.92
miR-1268a 0.00880  2.95 miR-410-3p 0.233 -1.46
miR-25-5p 0.01189  2.21 miR-331-3p 0.240 -2.21
miR-27b-3p 0.01797 -2.12 miR-663a 0.240 -2.61
miR-17-5p 0.01928 -1.35 miR-196b-5p 0.251 -2.58
miR-193b-3p 0.01961  3.78
miR-17-3p 0.03118 -3.03
miR-455-5p 0.03143 -1.40
miR-1275 0.03143  3.29
miR-203a 0.03456 -2.85
miR-663a 0.04074  2.39
agent. The latter observation of  differences in miRNA 
expression between EAC vs ESCC cell lines is consistent 
with the different tumor biology for EAC and ESCC. 
Furthermore, our study also identified dysregulated ex-
pression of  the miRNAs’ potential target genes [namely 
KRAS, TYMS, ABCC3 and CBL-B (5-FU resistant EAC) 
respectively ERBB2 and KRAS (5-FU resistant ESCC)] 
in a direction consistent with negative posttranscriptional 
control of  target gene expression via miR-27b-3p, miR-
193b-3p, miR-192-5p, miR-378 a-3p, miR-125a-5p and 
miR-18a-3p. 
These findings are consistent with other studies that 
suggest that these genes have an impact on chemothera-
py resistance in cancer. For example, overexpression of  
TYMS has been linked to resistance to TYMS-targeted 
chemotherapy agents such as 5-FU and methotrex-
ate[16], and ABCC3 is associated with chemotherapy 
resistance[17]. In addition, overexpression of  Cbl-b has 
been shown to downregulate both p-Akt and P-gp, and 
partially reverse resistance to chemotherapeutic agents in 
gastric cancer[18]. KRAS also has an impact on sensitivity 
to chemotherapy in colorectal cancer[13], and ERBB2 af-
fects chemotherapy resistance in breast cancer cells[19]. 
There is more than one possible explanation for 
dysregulation of  miRNA expression in (cisplatin and 
5-FU) resistant cell lines, and we can only speculate on 
this, based on currently known paradigms. For example, 
epigenetic changes such as DNA methylation or histone 
modification, that might occur during acquisition of  
chemotherapy resistance could directly impact upon the 
level of  transcription of  miRNA genes. The resulting 
changes in miRNA expression might then be important 
for further driving acquisition of  a highly chemotherapy 
resistant phenotype. However, recent reports also sug-
gest that many of  the identified miRNAs in our study 
have been shown to have an impact on chemotherapy 
resistance in other cancers. For example, members of  the 
miR-200 family, the miR-181 family, the let-7 family, or 
Summary of miRNA microarray results for the different chemotherapy resistant cell lines, including dysregulated miRNAs, stepup P-value and fold 
changes in expression, compared to sensitive controls. FU: 5-FU resistant cells; EAC: Esophageal adenocarcinoma cells; ESCC: Esophageal squamous cell 
carcinoma cells.
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single miRNAs such as miR-130a-3p, miR-221-3p/miR-
222-3p and miR-31-5p have been reported to be differen-
tially expressed in various chemotherapy resistant cancer 
cell lines, or to have an impact on sensitivity to anticancer 
treatment including chemotherapy and radiation[6]. The 
miRNA candidates in our study, for which we identified 
potential target genes, revealed a similar pattern, with 
miR-27b-3p, miR-193b-3p/miR-193b-5p, miR-192-5p, 
miR-378 a-3p or miR-125a-5p associated with resistance 
towards multiple chemotherapeutic agents in a number 
of  other tumor entities, including gastric[21] and colorectal 
cancer[22].
Data on esophageal cancer are still very rare, but the 
results from our study and other studies addressing this 
issue suggest that chemotherapy or radiotherapy resis-
tance in esophageal cancer is also modulated by miR-
NAs[23]. For example, Imanaka et al[24] found 10 miRNAs 
to be significantly dysregulated between nine ESCC cell 
lines with varying sensitivity towards cisplatin. However, 
as the authors used a model that compares miRNA ex-
pression between several different cell lines, it remains 
unclear whether the differences in miRNA expression 
are caused by variations in chemotherapy resistance or 
phenotypic differences between different cells originating 
from different human individuals. Data from other stud-
ies suggest that modulation of  the expression of  single 
miRNAs such as miR-27a-3p, miR-31-5p, miR-141-3p, 
miR-148a-3p, miR-200c-3p and miR-296-5p affect sensi-
tivity towards various chemotherapeutic agents or radia-
tion in esophageal cancer[7,24-28]. 
There are some limitations to the current study. 
Firstly, cell line experiments do not always yield results 
that can be directly translated to the clinical setting, as 
tumor tissues from patients often show considerable het-
erogeneity. Hence, the miRNAs identified in our study 
may not be relevant to all esophageal EACs or ESCCs in 
the clinical setting, and could be specific to the particular 
cell lines tested. This highlights the need for further con-
firmation in experiments using human tumor samples. 
However, most of  the miRNAs identified in our study 
have been reported in other tumor types, in both human 
tumor samples and cell culture settings, and this does 
suggest that the data from the current study is relevant. 
Secondly, the current study was limited to only two 
esophageal cancer cell lines, and their resistant sublines, 
and confirmation of  our results in other (sensitive and 
resistant) cell lines would provide further support to the 
findings. 
Finally, a thorough validation of  potential gene tar-
gets has not been undertaken at this stage, and we have 
not conducted functional analyses to confirm the role of  
miRNA in chemoresistance. 
However, the primary aims of  the current study were 
to investigate (1) if  chemotherapy resistant esophageal 
cancer cell lines exhibit specific miRNA expression pat-
terns, and (2) if  the expression of  potential resistance-rel-
evant target genes of  the dysregulated miRNAs is altered 
in the resistant cell lines. We were able to answer these 
questions with the current study. However, future experi-
ments exploring the downstream pathways in more detail 
will be needed and should help to understand how miR-
NAs might have an impact on chemotherapy resistance.
In conclusion, the current study demonstrated that 
chemotherapy resistant esophageal EAC and ESCC cells 
present distinct miRNA signatures, with a number of  
well known resistance relevant miRNAs differentially 
expressed in the derived cisplatin or 5-FU resistant cell 
lines. Furthermore, a number of  putative target genes 
that are known to have an impact on chemotherapy resis-
tance were dysregulated in the chemotherapy resistant cell 
lines in a direction consistent with negative posttranscrip-
tional control of  target gene expression via the respective 
miRNA, thereby implicating a potential mediatory effect 
in terms of  chemotherapy resistance development. This 
data presents initial basic research results pertinent to this 
topic, although the data remains limited by its in-vitro 
character. Nevertheless, the results from this study do 
support undertaking further in vivo studies that address 
whether miRNAs can be used as novel biomarkers for 
chemotherapy response prediction, or perhaps even eva-
luate modulation of  miRNAs as novel therapies for over-
coming chemotherapy resistance in esophageal cancer. 
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Table 2  Dysregulated microRNAs in resistant cells: quantitative real-time polymerase chain reaction validation
Cisplatin resistant EAC Cisplatin resistant ESCC 5-FU resistant EAC 5-FU resistant ESCC
Significantly dysregulated 
miRNAs in resistant 
variants
miR-455-3p (-3.06) miR-130a-3p (1.70) miR-378a-3p (-3.58) miR-935 (-2.29)
miR-200b-3p (-2.46) miR-192-5p (-2.32) miR-550a-3p (2.21)
let-7e-5p (-2.44) miR-210-3p (-2.19) miR-125a-5p (-2.20)
miR-181b-5p (-1.88) miR-194-5p (-2.01) miR-1226-3p (-2.12)
miR-125a-5p (-1.79) miR-222-3p (1.85) miR-99b-5p (-1.88)
miR-181a-5p (-1.63) miR-17-3p (-1.83) miR-18a-3p (-1.75)
miR-200b-5p (-1.63) miR-193b-3p (1.54)
miR-31-5p (-1.58) miR-31-5p (1.40)
miR-200a-3p (-1.57) miR-27b-3p (1.36)
miR-638 (1.55)
miR-191-5p (1.42)
Final quantitative real-time polymerase chain reaction validation results for the different chemotherapy resistant cell lines, including dysregulated miRNAs 
and fold changes in expression compared to chemotherapy sensitive controls. All listed miRNAs were significantly dysregulated compared to controls. FU: 
5-FU resistant cells; EAC: Esophageal adenocarcinoma cells; ESCC: Esophageal squamous cell carcinoma cells.
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COMMENTS
Background
Neoadjuvant (radio-) chemotherapy plays an important role in the treatment of 
patients with advanced esophageal cancer. However, individuals respond to 
these treatments in a variable fashion, and those who respond poorly to che-
motherapy probably undergo futile treatment. Identification of individuals who 
are unlikely to benefit before treatment starts is desirable as it would allow treat-
ment to be tailored to the individuals most likely to benefit. So far, no reliable 
biomarkers are available for prediction of response to neoadjuvant chemothera-
py in esophageal cancer patients. MicroRNAs might be promising candidates in 
this context, as there is some first evidence that microRNA expression has an 
impact on the response to chemotherapy in a number of other malignancies.  
Research frontiers
MicroRNAs are important regulators of global gene expression. To date, it is 
accepted that microRNAs play a crucial role in many physiological and patho-
logical processes, such as in the initiation and progression of cancer. Most im-
portantly, microRNAs have been demonstrated to impact on sensitivity towards 
various chemotherapeutic drugs including cisplatin and 5-FU resistant cells 
(5-FU) amongst others in a variety of cancers by regulating several resistance-
relevant intracellular pathways that control for example apoptosis, cell survival, 
DNA-repair and others.
Innovations and breakthroughs
By using an in-vitro model of acquired chemotherapy resistance in esophageal 
adeno- (EAC) and squamous cell carcinoma (ESCC) cells, the current study 
demonstrated that chemotherapy resistant esophageal EAC and ESCC cells 
present distinct miRNA signatures, with a number of well known resistance rel-
evant miRNAs differentially expressed in the derived cisplatin or 5-FU resistant 
cell lines. Furthermore, a number of putative target genes that are known to 
have an impact on chemotherapy resistance were dysregulated in the che-
motherapy resistant cell lines in a direction consistent with negative posttran-
scriptional control of target gene expression via the respective miRNA, thereby 
implicating a potential mediatory effect in terms of chemotherapy resistance 
development. In detail, miR-27b-3p, miR-193b-3p, miR-192-5p, miR-378 a-3p, 
miR-125a-5p and miR-18a-3p were dysregulated amongst others, consistent 
with negative posttranscriptional control of the expression of their potential tar-
gets KRAS, TYMS, ABCC3, CBL-B and ERBB2.
Applications
The results from this study do support undertaking further in vivo studies that 
address whether miRNAs can be used as novel biomarkers for chemotherapy 
response prediction, or perhaps even evaluate modulation of miRNAs as novel 
therapies for overcoming chemotherapy resistance in esophageal cancer.
Terminology
Chemotherapy resistance is a lack of response of cancer cells to drug-induced 
tumor growth inhibition. MicroRNAs are small non-coding RNA-molecules that 
control global gene expression on a post-transcriptional level. 
Peer review
The current study supports the hypothesis that microRNA expression has an 
impact on chemotherapy resistance in esophageal cancer. This provides a ba-
sis for further experimental and clinical investigations which could better tailor 
chemotherapy to individuals most likely to benefit, or identify and modulate 
chemotherapy resistance to achieve a better clinical response.
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